Page tree

Versions Compared

Key

  • This line was added.
  • This line was removed.
  • Formatting was changed.
Date

te

2018-10-16 13:30-17:30 local time, 20.30-0.30 UTC

Objectives

Discussion items


.

We have some discussions of extending the concept model to encompass additional attributes and allowed values.

These include:

  • | Direct substance | - analog to | Direct site |, e.g. a protein substance could be a proxy for genetic configuration.
  • Extend | Technique | allowed values to include << | Assessment scales | - was discussed previously (long time ago) to allow representation of Assessment scale observables. Scales typically includes an instrument used to collect information
    ItemDescriptionOwnerNotesAction
    1Welcome & apologies
    • Remember recording!



    2Conflicts of interest
    • None stated


    3Previous minutes
    • Approved


    4Susceptibility test products

    Draft editorial guidelines: Editorial Guidelines for Diagnostic Products Used for Susceptibility Testing

    It was decided to recommend representation the physical form of the susceptibility test product, and also to use the | has presentation strenght... | attributes (as opposed to other strength attributes).

    •  Daniel Karlsson to update the inception/elaboration document according to the decisions made
    •  Farzaneh Ashrafi to create a few examples of susceptibility test products

    55Vital Signs ObservablesSee this page. FHIR has a Vital Signs profile currently using LOINC terms and there is interest from the SNOMED on FHIR group (and it's members) to find the appropriate SNOMED CT Observables. However, these would require modelling, and perhaps re-modelling.6Diastolic arterial pressure and how to go forward with existing Observables

    Together with EAG

    Immediately after coffee

    See comments on this page.

    The FSNs are generally under-specified compared to how concepts have been used. We need to decide whether to retire, rename, remodel, add or leave as is.

    E.g. the blood pressure observables FSNs do not specify time aspect. Can we assume that they are single point in time or not?

    The guidance given by the EAG was that we should allow more consideration of reasonable clinical interpretation and also to allow updating and clarification of FSNs if deemed necessary. Data concerning clinical use of the concepts should be used to inform decisions. Ambiguous concepts which are not in significant use may be retired.

    As this might disrupt implementations the updated guidance should be discussed with the MF and CMAG.

    •  Daniel Karlsson to write a briefing note to MF and CMAG regarding the updated guidance

    6Observables MRCM

    We have previously had some discussions of extending the concept model to encompass additional attributes and allowed values.

    These include:

    • | Direct substance | - analog to | Direct site |, e.g. a protein substance could be a proxy for genetic configuration, with the range of << 105590001 | Substance |.
    • Extend | Technique | allowed values to include << | Assessment scales | - was discussed previously (long time ago) to allow representation of Assessment scale observables. Scales typically includes an instrument used to collect information.

    Presentation here

    It was decided to recommend making the above changes to the MRCM.



    7Primary tumor site


    8Target observables


    Copied from the Vital signs incept./elaborat. document:

    Target observables

    Among the 46680005 | Vital sign (observable entity) | observables, there are a few "target" observables: 428420003 | Target heart rate (observable entity) |, 315612005 | Target systolic blood pressure (observable entity) |, and 315613000 | Target diastolic blood pressure (observable entity) |. These concepts would not be considered vital signs according to the definition used in this document. While the representation of such targets have not yet been elaborated on, it is clear that a target observable is distinct from a "ordinary" observable, particularly true for e.g. 390734006 | Target weight (observable entity) | and 27113001 | Body weight (observable entity) |. There are related JIRA tickets: IHTSDO-457PCP-5IHTSDO-39 and also some potentially related tickets: IHTSDO-356IHTSDO-308.

    Here is a presentation from a previous Observables meeting.

    Here is an updated presentation

    8Observables MRCMDaniel Karlsson

    .



    Presentation here

    9
    Primary tumor siteJames R. CampbellObservables for clinical trialtrials


    910Next meeting
    • 2018-11-19 (or do we want to go back to twice per month?)



    911AOB


    Meeting Files

    Attachments

    Previous Meetings

    Content Report Table
    maxResults12
    showCommentsCounttrue
    spacesOBSERVABLE
    labelsmeeting-agenda

    More Zoom details

    Topic: Observables meeting

    Time: this is a recurring meeting Meet anytime

    Join from PC, Mac, Linux, iOS or Android:
    https://snomed.zoom.us/j/992630241

    Or Telephone:
    Dial:
    +46 (0) 8 4468 2488 (SE Toll)
    +61 (0) 2 8015 2088 (AU Toll)
    +32 (0) 2 588 4188 (BE Toll)
    +1 647 558 0588 (CA Toll)
    +56 41 256 0288 (CL Toll)
    +420 2 2888 2388 (CZ Toll)
    +45 89 88 37 88 (DK Toll)
    +372 880 1188 (EE Toll)
    +852 5808 6088 (HK Toll)
    +353 (0) 1 691 7488 (IE Toll)
    +972 (0) 3 978 6688 (IL Toll)
    +370 5214 1488 (LT Toll)
    +60 3 9212 1727 (MY Toll)
    +356 2778 1288 (MT Toll)
    +31 (0) 20 241 0288 (NL Toll)
    +64 (0) 9 801 1188 (NZ Toll)
    +64 (0) 4 831 8959 (NZ Toll)
    +47 2396 0588 (NO Toll)
    +48 22 307 3488 (PL Toll)
    +351 308 804 188 (PT Toll)
    +65 3158 7288 (SG Toll)
    +421 233 056 888 (SK Toll)
    +386 1888 8788 (SI Toll)
    +34 91 198 0188 (ES Toll)
    +41 (0) 31 528 0988 (CH Toll)
    +44 (0) 20 3695 0088 (GB Toll)
    +1 408 638 0968 (US Toll)
    +1 646 876 9923 (US Toll)
    +1 669 900 6833 (US Toll)

    Meeting ID: 992 630 241

    International numbers available: https://snomed.zoom.us/zoomconference?m=AQWV2VqAIGYWMcMapl9CoYjsaj1TVS7K